Discontinued — last reported Q4 '22
Current Assets
Raw materials
Alnylam Pharmaceuticals Raw materials decreased by 17.6% to $11.69M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 50.0%, from $23.40M to $11.69M. Over 5 years (FY 2020 to FY 2025), Raw materials shows a downward trend with a -25.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ3 2017
Last reportedQ4 2022
Parent metricInventories
How to read this metric
High levels may signal proactive supply chain hedging against shortages, while low levels could indicate lean inventory management or potential supply risks.
Detailed definition
The cost of basic components and supplies held for use in the manufacturing of finished products. This inventory serves...
Peer comparison
Standard across manufacturing sectors; levels vary based on supply chain strategy and lead times.
Metric ID:
inv_raw_materialsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $54.34M | $65.16M | $14.75M | $20.37M | $19.14M | $17.72M | $22.32M | $22.88M | $17.45M | $20.12M | $23.35M | $25.40M | $26.02M | $22.37M | $23.97M | $23.40M | $22.87M | $22.25M | $14.18M | $11.69M |
| QoQ Change | — | +19.9% | -77.4% | +38.1% | -6.0% | -7.4% | +25.9% | +2.5% | -23.7% | +15.3% | +16.0% | +8.8% | +2.4% | -14.1% | +7.2% | -2.4% | -2.3% | -2.7% | -36.3% | -17.6% |
| YoY Change | — | — | — | — | -64.8% | -72.8% | +51.2% | +12.3% | -8.8% | +13.6% | +4.6% | +11.0% | +49.1% | +11.2% | +2.7% | -7.9% | -12.1% | -0.5% | -40.8% | -50.0% |
| % of Inventories | 64.4% | 66.6% | 17.1% | 25.9% | 21.5% | 15.3% | 17.3% | 17.3% | 17.4% | 21.0% | 26.2% | 27.0% | 31.0% | 29.4% | 30.5% | 35.7% | 31.9% | 29.5% | 17.1% | 13.9% |
| Share Change | — | +2.1pp | -49.5pp | +8.9pp | -4.4pp | -6.2pp | +2.0pp | +0.0pp | +0.0pp | +3.6pp | +5.2pp | +0.8pp | +4.0pp | -1.6pp | +1.1pp | +5.2pp | -3.8pp | -2.4pp | -12.4pp | -3.2pp |
Range$11.69M – $65.16M
CAGR-27.6%
Avg YoY Growth-6.4%
Median YoY Growth+1.1%
Current Streak5 quarters decline
Raw materials at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's raw materials?
- Alnylam Pharmaceuticals (ALNY) reported raw materials of $11.69M in Q1 2026.
- How has Alnylam Pharmaceuticals's raw materials changed year-over-year?
- Alnylam Pharmaceuticals's raw materials decreased by 50.0% year-over-year, from $23.40M to $11.69M.
- What is the long-term trend for Alnylam Pharmaceuticals's raw materials?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's raw materials has grown at a -25.9% compound annual growth rate (CAGR), from $63.46M to $14.18M.
- What does raw materials mean?
- The value of basic materials and supplies waiting to be used in production.